Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 1Leukemia, Myelomonocytic, Chronic 1COVID-19 1

Interventions

Cyclophosphamide 78fludarabine phosphate 77Azacitidine 76Peripheral Blood Stem Cell Transplantation 63Busulfan 53Mycophenolic Acid 51Whole-Body Irradiation 50Tacrolimus 48Cytarabine 43Cyclosporine 43Methotrexate 37Decitabine 36Filgrastim 32Antilymphocyte Serum 30venetoclax 27Radiotherapy 25Melphalan 23fludarabine 22Etoposide 18Methylprednisolone 17Biopsy 15Cyclosporins 14Specimen Handling 13Injections 13Granulocyte Colony-Stimulating Factor 13Flow Cytometry 13Cord Blood Stem Cell Transplantation 13decitabine and cedazuridine drug combination 12Idarubicin 12Stem Cell Transplantation 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Chronic × lenzilumab × Clear all
NCT02546284 2020-02-28

Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)

Humanigen, Inc.

Phase 1 Completed
15 enrolled
Other hematologic neoplasm

Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡